Company intelligence / Profile preview

NeuroDex

Boston, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

NeuroDex has demonstrated robust preliminary data for the identification of alpha-synuclein and TDP-43 in blood, enabling early, non-invasive detection of underlying brain pathologies in dementias and ALS. Ongoing clinical validation aims to establish its exosome-based assay as a powerful tool for stratifying trial populations and guiding precision medicine approaches in neurodegeneration.[1][4][5]

Therapeutic areas: Neurology
Modalities: DiagnosticExosome-based therapy
Industry: Protein Biomarker Diagnostics

Partnerships

Multiple unnamed pharmaceutical and biotech collaborations (supporting clinical trials as exploratory biomarkers)[1]

Beyond the preview

Go deeper on NeuroDex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroDex.

Explore the full profile